{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:12:00Z","timestamp":1789884720512,"version":"4.0.1"},"reference-count":100,"publisher":"Impact Journals, LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,1,5]]},"DOI":"10.18632\/oncotarget.23359","type":"journal-article","created":{"date-parts":[[2017,12,18]],"date-time":"2017-12-18T04:51:11Z","timestamp":1513572671000},"page":"2951-2961","source":"Crossref","is-referenced-by-count":38,"title":["Aptamer: A potential oligonucleotide nanomedicine in the diagnosis and treatment of hepatocellular carcinoma"],"prefix":"10.18632","volume":"9","author":[{"given":"Rusdina Bte","family":"Ladju","sequence":"first","affiliation":[{"name":"Fondazione Italiana Fegato, AREA Science Park Basovizza, Trieste, Italy"},{"name":"Faculty of Medicine, Hasanuddin University, Makassar, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devis","family":"Pascut","sequence":"additional","affiliation":[{"name":"Fondazione Italiana Fegato, AREA Science Park Basovizza, Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Nasrum","family":"Massi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Hasanuddin University, Makassar, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Tiribelli","sequence":"additional","affiliation":[{"name":"Fondazione Italiana Fegato, AREA Science Park Basovizza, Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caecilia H.C.","family":"Sukowati","sequence":"additional","affiliation":[{"name":"Fondazione Italiana Fegato, AREA Science Park Basovizza, Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,12,16]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Bray","year":"2015","journal-title":"Int J Cancer"},{"key":"2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jhep.2017.03.011","article-title":"Global trends and predictions in hepatocellular carcinoma mortality","volume":"67","author":"Negri","year":"2017","journal-title":"J Hepatol"},{"key":"3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","article-title":"Global cancer statistics","volume":"61","author":"Forman","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"4","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0140-6736(11)61347-0","article-title":"Hepatocellular carcinoma","volume":"379","author":"Bruix","year":"2012","journal-title":"Lancet"},{"key":"5","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1016\/S0168-8278(12)60009-9","article-title":"Management of HCC","volume":"56","author":"Bruix","year":"2012","journal-title":"J Hepatol"},{"key":"6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jhep.2016.09.012","article-title":"Personalized treatment of patients with very early hepatocellular carcinoma","volume":"66","author":"Pawlik","year":"2017","journal-title":"J Hepatol"},{"key":"7","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"56","author":"European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer","year":"2012","journal-title":"J Hepatol"},{"key":"8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0168-8278(02)00360-4","article-title":"Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy","volume":"38","author":"Makuuchi","year":"2003","journal-title":"J Hepatol"},{"key":"9","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.dld.2014.07.012","article-title":"Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation","volume":"46","author":"Barone","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/hep.27388","article-title":"Emerging trends in hepatocellular carcinoma incidence and mortality","volume":"61","author":"Lim","year":"2015","journal-title":"Hepatol"},{"key":"11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Milstein","year":"1975","journal-title":"Nature"},{"key":"12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/nbt.1791","article-title":"Beyond natural antibodies: the power ofdisplay technologies","volume":"29","author":"McCafferty","year":"2011","journal-title":"Nat Biotechnol"},{"key":"13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Baty","year":"2009","journal-title":"Br J Pharmacol"},{"key":"14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jhep.2016.04.004","article-title":"Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma","volume":"65","author":"Okusaka","year":"2016","journal-title":"J Hepatol"},{"key":"15","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00280-017-3241-9","article-title":"Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)","volume":"79","author":"Lin","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"16","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ymthe.2017.03.023","article-title":"FDA-approved oligonucleotide therapies in 2017","volume":"25","author":"Castanotto","year":"2017","journal-title":"Mol Ther J"},{"key":"17","first-page":"668","article-title":"Tumor targeting by an aptamer","volume":"47","author":"Schmidt","year":"2006","journal-title":"J Nucl Med"},{"key":"18","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/hum.2015.070","article-title":"Oligonucleotide therapies: The past and the present","volume":"26","author":"Smith","year":"2015","journal-title":"Hum Gene Ther"},{"key":"19","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1126\/science.287.5454.820","article-title":"Adaptive recognition by nucleic acid aptamers","volume":"287","author":"Patel","year":"2000","journal-title":"Science"},{"key":"20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1146\/annurev.med.56.062904.144915","article-title":"Aptamers: an emerging class of therapeutics","volume":"56","author":"Sullenger","year":"2005","journal-title":"Annu Rev Med"},{"key":"21","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1002\/smll.201403073","article-title":"Aptamers and their applications in nanomedicine","volume":"11","author":"Zu","year":"2015","journal-title":"Small"},{"key":"22","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.1038\/mtna.2014.32","article-title":"Oligonucleotide aptamers: new tools for targeted cancer therapy","volume":"3","author":"Zu","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"23","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/anie.200804643","article-title":"The chemical biology of aptamers","volume":"48","author":"Mayer","year":"2009","journal-title":"Angew Chem Int Ed Engl"},{"key":"24","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrd3141","article-title":"Aptamers as therapeutics","volume":"9","author":"Ellington","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"25","first-page":"122","article-title":"Nucleic acid aptamers as adjuncts to vaccine development","volume":"8","author":"Becker","year":"2006","journal-title":"Curr Opin Mol Ther"},{"key":"26","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1172\/JCI69856","article-title":"Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity","volume":"124","author":"Gilboa","year":"2014","journal-title":"J Clin Invest"},{"key":"27","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1021\/bi0024052","article-title":"Editing by a tRNA synthetase: DNA aptamer-induced translocation and hydrolysis of a misactivated amino acid","volume":"40","author":"Schimmel","year":"2001","journal-title":"Biochemistry"},{"key":"28","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1073\/pnas.93.7.2755","article-title":"Protein synthesis editing by a DNA aptamer","volume":"93","author":"Schimmel","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"29","doi-asserted-by":"publisher","first-page":"13446","DOI":"10.18632\/oncotarget.7178","article-title":"Aptamers: A promising chemical antibody for cancer therapy","volume":"7","author":"Qiao","year":"2016","journal-title":"Oncotarget"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.3390\/ph10010032","article-title":"Aptamers: Biomedical interest and applications","volume":"10","author":"Berzal-Herranz","year":"2017","journal-title":"Pharm Basel"},{"key":"31","doi-asserted-by":"publisher","first-page":"13624","DOI":"10.3390\/s131013624","article-title":"Aptamers as theranostic agents: modifications, serum stability and functionalisation","volume":"13","author":"Li","year":"2013","journal-title":"Sensors"},{"key":"32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Adamis","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"33","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1136\/bjo.2009.174946","article-title":"Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study","volume":"94","author":"Goldbaum","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"34","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1158\/1535-7163.MCT-06-0172","article-title":"Discovery and development of anticancer aptamers","volume":"5","author":"Kelland","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"35","doi-asserted-by":"publisher","first-page":"931","DOI":"10.7150\/thno.9663","article-title":"Progress in aptamer-mediated drug delivery vehicles for cancer targeting and its implications in addressing chemotherapeutic challenges","volume":"4","author":"Zhang","year":"2014","journal-title":"Theranostics"},{"key":"36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-1-4939-3197-2_3","article-title":"Developing aptamers by cell-based SELEX","volume":"1380","author":"de Franciscis","year":"2016","journal-title":"Methods Mol Biol"},{"key":"37","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.7150\/thno.11711","article-title":"Superior performance of aptamer in tumor penetration over antibody: implication of aptamer-based theranostics in solid tumors","volume":"5","author":"Dean","year":"2015","journal-title":"Theranostics"},{"key":"38","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1039\/c5an01995h","article-title":"Aptamers: versatile molecular recognition probes for cancer detection","volume":"141","author":"Zu","year":"2016","journal-title":"The Analyst"},{"key":"39","first-page":"27","article-title":"RNA aptamers and their therapeutic and diagnostic applications","volume":"4","author":"Zhang","year":"2013","journal-title":"Int J Biochem Mol Biol"},{"key":"40","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Gold","year":"1990","journal-title":"Science"},{"key":"41","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/346818a0","article-title":"selection of RNA molecules that bind specific ligands","volume":"346","author":"Szostak","year":"1990","journal-title":"Nature"},{"key":"42","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.bioeng.2007.06.001","article-title":"SELEX--a (r)evolutionary method to generate high-affinity nucleic acid ligands","volume":"24","author":"Strehlitz","year":"2007","journal-title":"Biomol Eng"},{"key":"43","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1038\/mtna.2014.34","article-title":"New technologies provide quantum changes in the scale, speed, and success of SELEX methods and aptamer characterization","volume":"3","author":"Lis","year":"2014","journal-title":"Mol Ther Nucleic Acids"},{"key":"44","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.biotechadv.2015.02.008","article-title":"Current approaches in SELEX: An update to aptamer selection technology","volume":"33","author":"Ruml","year":"2015","journal-title":"Biotechnol Adv"},{"key":"45","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3390\/ijms17030358","article-title":"Molecular selection, modification and development of therapeutic oligonucleotide aptamers","volume":"17","author":"Zhang","year":"2016","journal-title":"Int J Mol Sci"},{"key":"46","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.3389\/fmicb.2016.01909","article-title":"Immuno Affinity SELEX for simple, rapid, and cost-effective aptamer enrichment and identification against Aflatoxin B1","volume":"7","author":"Kingston","year":"2016","journal-title":"Front Microbiol"},{"key":"47","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.biotechadv.2015.02.008","article-title":"Current approaches in SELEX: An update to aptamer selection technology","volume":"33","author":"Ruml","year":"2015","journal-title":"Biotechnol Adv"},{"key":"48","doi-asserted-by":"publisher","first-page":"44409","DOI":"10.1038\/srep44409","article-title":"Aptamer-based field-effect biosensor for tenofovir detection","volume":"7","author":"Carrara","year":"2017","journal-title":"Sci Rep"},{"key":"49","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.bios.2017.02.024","article-title":"A reusable aptasensor of thrombin based on DNA machine employing resonance light scattering technique","volume":"92","author":"Li","year":"2017","journal-title":"Biosens Bioelectron"},{"key":"50","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2174\/1568026615666150413154233","article-title":"Aptamers: molecular tools for medical diagnosis","volume":"15","author":"Bayrac","year":"2015","journal-title":"Curr Top Med Chem"},{"key":"51","doi-asserted-by":"crossref","unstructured":"Chen, Liu, Yu, Zhong, Lu, Zhang, Liao, Liu, Pu, Qiu, Zhang, Liu, Tan. Advances in the development of aptamer drug conjugates for targeted drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016; p. 9. https:\/\/doi.org\/10.1002\/wnan.1438.","DOI":"10.1002\/wnan.1438"},{"key":"52","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1517\/17425247.2015.966681","article-title":"Cell-specific aptamers and their conjugation with nanomaterials for targeted drug delivery","volume":"12","author":"Liu","year":"2015","journal-title":"Expert Opin Drug Deliv"},{"key":"53","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1021\/mp500047b","article-title":"Aptamer-targeted DNA nanostructures for therapeutic delivery","volume":"11","author":"Bermudez","year":"2014","journal-title":"Mol Pharm"},{"key":"54","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2174\/1568026615666150413153928","article-title":"Aptamer-targeted oligonucleotide theranostics: a smarter approach for brain delivery and the treatment of neurological diseases","volume":"15","author":"Kanwar","year":"2015","journal-title":"Curr Top Med Chem"},{"key":"55","doi-asserted-by":"publisher","first-page":"23","DOI":"10.7150\/thno.10202","article-title":"Nucleic acid aptamer-guided cancer therapeutics and diagnostics: the next generation of cancer medicine","volume":"5","author":"Duan","year":"2015","journal-title":"Theranostics"},{"key":"56","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201603990","article-title":"A Smart responsive dual aptamers-targeted bubble-generating nanosystem for cancer triplex therapy and ultrasound imaging","volume":"13","author":"Du","year":"2017","journal-title":"Small"},{"key":"57","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.exer.2006.02.010","article-title":"Pegaptanib for the treatment of age-related macular degeneration","volume":"83","author":"Wang","year":"2006","journal-title":"Exp Eye Res"},{"key":"58","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1021\/nn507494p","article-title":"Aptamer nanomedicine for cancer therapeutics: barriers and potential for translation","volume":"9","author":"Leong","year":"2015","journal-title":"ACS Nano"},{"key":"59","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s10637-013-0045-6","article-title":"A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma","volume":"32","author":"Laber","year":"2014","journal-title":"Invest New Drugs"},{"key":"60","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/abbs\/gmt130","article-title":"Screening and verification of ssDNA aptamers targeting human hepatocellular carcinoma","volume":"46","author":"Liu","year":"2014","journal-title":"Acta Biochim Biophys Sin"},{"key":"61","doi-asserted-by":"publisher","first-page":"10897","DOI":"10.1038\/srep10897","article-title":"Aptamer-based sandwich assay and its clinical outlooks for detecting lipocalin-2 in Hepatocellular Carcinoma (HCC)","volume":"5","author":"Kim","year":"2015","journal-title":"Sci Rep"},{"key":"62","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1016\/j.biomaterials.2013.02.018","article-title":"Recognition and capture of metastatic hepatocellular carcinoma cells using aptamer-conjugated quantum dots and magnetic particles","volume":"34","author":"Li","year":"2013","journal-title":"Biomaterials"},{"key":"63","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.7150\/thno.15284","article-title":"Aptamer-mediated transparent-biocompatible nanostructured surfaces for 10.7150\/thno.15284. hepotocellular circulating tumor cells enrichment","volume":"6","author":"Xiong","year":"2016","journal-title":"Theranostics"},{"key":"64","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1021\/ac701962v","article-title":"Identification of liver cancer-specific aptamers using whole live cells","volume":"80","author":"Tan","year":"2008","journal-title":"Anal Chem"},{"key":"65","doi-asserted-by":"publisher","first-page":"4956","DOI":"10.1021\/ac500375p","article-title":"Ultrasensitive detection of human liver hepatocellular carcinoma cells using a label-free aptasensor","volume":"86","author":"Tiwari","year":"2014","journal-title":"Anal Chem"},{"key":"66","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.bios.2015.12.060","article-title":"Label-free detection of liver cancer cells by aptamer-based microcantilever biosensor","volume":"79","author":"Zhang","year":"2016","journal-title":"Biosens Bioelectron"},{"key":"67","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.aca.2015.05.027","article-title":"A repeatable assembling and disassembling electrochemical aptamer cytosensor for ultrasensitive and highly selective detection of human liver cancer cells","volume":"885","author":"Mo","year":"2015","journal-title":"Anal Chim Acta"},{"key":"68","doi-asserted-by":"crossref","unstructured":"Sun, Lu, Wang, Zhang, Chen. Voltammetric aptamer based detection of HepG2 tumor cells by using an indium tin oxide electrode array and multifunctional nanoprobes. Microchim Acta. 2017; pp. 1\u201310. https:\/\/doi.org\/10.1007\/s00604-017-2376-z.","DOI":"10.1007\/s00604-017-2376-z"},{"key":"69","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/978-1-60761-609-2_10","article-title":"Fluorescent silica nanoparticles for cancer imaging","volume":"624","author":"Santra","year":"2010","journal-title":"Methods Mol Biol"},{"key":"70","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s11671-017-1890-6","article-title":"Aptamer combined with fluorescent silica nanoparticles for detection of hepatoma cells","volume":"12","author":"Lu","year":"2017","journal-title":"Nanoscale Res Lett"},{"key":"71","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.3892\/or.2017.5527","article-title":"An \u201cactivatable\u201d aptamer-based fluorescence probe for the detection of HepG2 cells","volume":"37","author":"Lu","year":"2017","journal-title":"Oncol Rep"},{"key":"72","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1517\/17425247.3.3.311","article-title":"Nanoparticle-aptamer bioconjugates for cancer targeting","volume":"3","author":"Langer","year":"2006","journal-title":"Expert Opin Drug Deliv"},{"key":"73","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1073\/pnas.0601755103","article-title":"Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy","volume":"103","author":"Langer","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"74","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/SLA.0b013e31823e3a1c","article-title":"Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model","volume":"255","author":"Kuo","year":"2012","journal-title":"Ann Surg"},{"key":"75","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/mt.2008.235","article-title":"RNA Aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells","volume":"17","author":"Kuo","year":"2009","journal-title":"Mol Ther J Am Soc Gene Ther"},{"key":"76","doi-asserted-by":"publisher","first-page":"e0136673","DOI":"10.1371\/journal.pone.0136673","article-title":"A synthetic aptamer-drug adduct for targeted liver cancer therapy","volume":"10","author":"Liu","year":"2015","journal-title":"PloS One"},{"key":"77","doi-asserted-by":"publisher","first-page":"e33434","DOI":"10.1371\/journal.pone.0033434","article-title":"Targeted delivery of chemotherapy agents using a liver cancer-specific aptamer","volume":"7","author":"Tan","year":"2012","journal-title":"PloS One"},{"key":"78","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ijpharm.2016.04.031","article-title":"Aptamer targeting of the elongation factor 1A impairs hepatocarcinoma cells viability and potentiates bortezomib and idarubicin effects","volume":"506","author":"Grassi","year":"2016","journal-title":"Int J Pharm"},{"key":"79","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s11051-016-3633-5","article-title":"Targeted therapy of hepatocellular carcinoma with aptamer-functionalized biodegradable nanoparticles","volume":"18","author":"Betancourt","year":"2016","journal-title":"J Nanoparticle Res"},{"key":"80","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.2147\/IJN.S108128","article-title":"Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma","volume":"11","author":"Li","year":"2016","journal-title":"Int J Nanomedicine"},{"key":"81","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jconrel.2017.05.017","article-title":"Aptamer-mediated gene therapy enhanced antitumor activity against human hepatocellular carcinomaand","volume":"258","author":"Zhong","year":"2017","journal-title":"J Control Release"},{"key":"82","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ejpb.2016.12.009","article-title":"andevaluation of anti-nucleolin-targeted magnetic PLGA nanoparticles loaded with doxorubicin as a theranostic agent for enhanced targeted cancer imaging and therapy","volume":"113","author":"Ramezani","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"key":"83","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.bbrc.2011.11.153","article-title":"Regression of hepatocarcinoma cells using RNA aptamer specific to alpha-fetoprotein","volume":"417","author":"Lee","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"84","doi-asserted-by":"crossref","unstructured":"Dong, Tan, Ye, Liu, Chen, Hu, Wen, Liu, Cao, Kang, Fan, Guo, Wu. Screening and identifying a novel ssDNA aptamer against alpha-fetoprotein using CE-SELEX. Sci Rep. 2015; p. 5. https:\/\/doi.org\/10.1038\/srep15552.","DOI":"10.1038\/srep15552"},{"key":"85","doi-asserted-by":"publisher","first-page":"11699","DOI":"10.1021\/acs.analchem.6b03283","article-title":"Nature-inspired smart DNA nanodoctor for activatablecancer imaging and in situ drug release based on recognition-triggered assembly of split aptamer","volume":"88","author":"Wang","year":"2016","journal-title":"Anal Chem"},{"key":"86","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ijpharm.2014.07.036","article-title":"Smart magnetic nanoparticle-aptamer probe for targeted imaging and treatment of hepatocellular carcinoma","volume":"473","author":"Thongtem","year":"2014","journal-title":"Int J Pharm"},{"key":"87","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nbt.1560","article-title":"Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors","volume":"27","author":"Giangrande","year":"2009","journal-title":"Nat Biotechnol"},{"key":"88","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ymeth.2016.03.008","article-title":"Enhancing aptamer function and stability viaselection using modified nucleic acids","volume":"106","author":"Heemstra","year":"2016","journal-title":"Methods"},{"key":"89","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1089\/nat.2017.0680","article-title":"Effect of chemical modifications on aptamer stability in serum","volume":"27","author":"Levy","year":"2017","journal-title":"Nucleic Acid Ther"},{"key":"90","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1261\/rna.334307","article-title":"Combining SELEX and the yeast three-hybrid system forselection and classification of RNA aptamers","volume":"13","author":"Feldbr\u00fcgge","year":"2007","journal-title":"RNA"},{"key":"91","doi-asserted-by":"publisher","first-page":"742","DOI":"10.14348\/molcells.2014.0208","article-title":"Identification of DNA aptamers toward epithelial cell adhesion molecule via cell-SELEX","volume":"37","author":"Bae","year":"2014","journal-title":"Mol Cells"},{"key":"92","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1515\/hsz-2011-0253","article-title":"One round of SELEX for the generation of DNA aptamers directed against KLK6","volume":"393","author":"Sotiropoulou","year":"2012","journal-title":"Biol Chem"},{"key":"93","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1093\/nar\/gkp408","article-title":"In silico selection of RNA aptamers","volume":"37","author":"Stone","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"94","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1021\/ja037832s","article-title":"evolution of functional DNA using capillary electrophoresis","volume":"126","author":"Bowser","year":"2004","journal-title":"J Am Chem Soc"},{"key":"95","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1007\/s12010-016-2193-6","article-title":"Selection and identification of chloramphenicol-specific DNA aptamers by Mag-SELEX","volume":"180","author":"Li","year":"2016","journal-title":"Appl Biochem Biotechnol"},{"key":"96","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.18632\/oncotarget.6608","article-title":"Identification of TIM3 2\u2019-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy","volume":"7","author":"Pastor","year":"2016","journal-title":"Oncotarget"},{"key":"97","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1089\/nat.2016.0611","article-title":"Ligand-guided selection of target-specific aptamers: A screening technology for identifying specific aptamers against cell-surface proteins","volume":"26","author":"Mallikaratchy","year":"2016","journal-title":"Nucleic Acid Ther"},{"key":"98","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.biochi.2016.09.018","article-title":"The efficient cell-SELEX strategy, Icell-SELEX, using isogenic cell lines for selection and counter-selection to generate RNA aptamers to cell surface proteins","volume":"131","author":"Nakamura","year":"2016","journal-title":"Biochimie"},{"key":"99","doi-asserted-by":"publisher","first-page":"18460","DOI":"10.1073\/pnas.1315866110","article-title":"Quantitative selection and parallel characterization of aptamers","volume":"110","author":"Soh","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"100","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1016\/j.bmcl.2013.01.040","article-title":"Cell-SELEX based selection and characterization of DNA aptamer recognizing human hepatocarcinoma","volume":"23","author":"Shimizu","year":"2013","journal-title":"Bioorg Med Chem Lett"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.23359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T10:49:59Z","timestamp":1589021399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.23359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,16]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,1,5]]}},"alternative-id":["23359","29416827"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.23359","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,16]]}}}